Reconnaissance Energy Africa Ltd Warrants (27/05/2024) Stock (OTC: RECWF)

Reconnaissance Energy Africa Ltd Warrants (27/05/2024) (OTC:RECWF) Stock, Quote.Headers.trade-ideas

Reconnaissance Energy Africa Ltd Warrants (27/05/2024)

Baird analyst Colin Sebastian maintains Corsair Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) with a Neutral and lowers the price target from $10 to $8.

News

Price Target

Analyst Ratings

CRSR

Baird Maintains Neutral on Corsair Gaming, Lowers Price Target to $8

Keybanc analyst Alex Markgraff maintains Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Overweight and lowers the price target from $145 to $135.

Keybanc Maintains Overweight on Global Payments, Lowers Price Target to $135

In October 2023, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">pipeline and cut costs</a>.
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
Sanofi&#8217;s consumer health unit boasts a portfolio that includes popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.&nbsp;
According to a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-24/sanofi-said-to-get-binding-bids-from-cd-r-pai-for-consumer-arm?srnd=prognosis&amp;embedded-checkout=true" rel="noreferrer noopener">report</a>, two private equity firms, Clayton Dubilier &amp; Rice and PAI Partners, made separate bids for Sanofi&#8217;s consumer health division.
The update pushes the European pharma giant closer to one of the largest European deals this year, which could value the unit at 15 billion euros ($16.8 billion) or more, the Bloomberg report added.
The separation is expected to occur by Q4 2024 by creating a publicly listed entity headquartered in France.
In July, Goldman Sachs Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and&nbsp;Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39755459/sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-6-5b-financing" rel="noreferrer noopener">Sanofi&#8217;s&nbsp;consumer health division</a>.
The move highlighted banks&#8217; interest in supporting leveraged buyouts through pre-arranged financing.
Sanofi may opt for a spinoff of its consumer health business if the offers aren&#8217;t appealing, Bloomberg noted, citing sources. A company spokesperson told Bloomberg that Sanofi is evaluating potential separation options, with the earliest possible transaction happening in the fourth quarter of this year, and noted that preparations are progressing as planned.
In November 2023, Sanofi reportedly initiated talks with Rothschild &amp; Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35823034/major-buyout-firms-eye-sanofis-consumer-health-division-spinoff-valued-over-20b" rel="noreferrer noopener">at over $20 billion</a>.&nbsp;
Rival pharma giants&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;and&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) split their consumer healthcare units&nbsp;Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Kenvue Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), respectively.
Price Action: SNY stock closed at $57.62&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/09/41012667/healthcare-software-giant-epic-systems-hit-with-lawsuit-over-alleged-monopolistic-practices" target="_blank" rel="noreferrer noopener">Healthcare Software Giant Epic Systems Hit With Lawsuit Over Alleged Monopolistic Practices</a>.</li>
</ul>
Photo via Company

Biotech

Large Cap

Health Care

Rumors

Media

General

KVUE

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff

Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/ACN/earnings">opening bell on Thursday, Sept. 26</a>.
Analysts expect the Dublin, Ireland-based company to report quarterly earnings at $2.78 per share, up from $2.71 per share in the year-ago period. Accenture projects to report revenue of $16.38 billion for the quarter, compared to $15.99 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 16, Accenture Federal Services won a $190M million U.S. Department of State Data and Systems Engineering contract.
Accenture shares gained 0.1% to close at $339.62 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f777c10bd99100018a435e/tien-tsin-huang">JP Morgan analyst Tien-Tsin Huang</a> maintained an Overweight rating and cut the price target from $376 to $370 on Sept. 24. This analyst has an accuracy rate of 61%.</li>
<li>Mizuho analyst Dan Doelev maintained an Outperform rating and boosted the price target from $352 to $365 on Sept. 18. This analyst has an accuracy rate of 63%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591ed97e290fa70001e6c69f/ashwin-shirvaikar">Citigroup analyst Ashwin Shirvaikar</a> maintained a Buy rating and raised the price target from $350 to $405 on Sept. 17. This analyst has an accuracy rate of 72%.</li>
<li>TD Cowen analyst Bryan Bergin maintained a Hold rating and raised the price target from $293 to $321 on Sept. 12. This analyst has an accuracy rate of 62%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5845b510ee7bf6000154d079/james-faucette">Morgan Stanley analyst James Faucette</a> downgraded the stock from Overweight to Equal-Weight rating and slashed the price target from $382 to $300 on June 26. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying ACN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="509" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-1024x509.png" alt="" class="wp-image-564748" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-1024x509.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192-768x382.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25021809/image-192.png 1341w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41003853/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Markets

Trading Ideas

Accenture Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>ORKA-001 has an NHP half-life of 30.3 days following SQ administration and 33.8 days following IV administration, over three times longer than risankizumab and one of the longest NHP half-lives observed for an extended half-life antibody. Projections of ORKA-001 pharmacokinetics (PK) in humans indicate that a human half-life of approximately 50 days could enable dosing once every six months, while a human half-life of approximately 75 days could enable once-yearly dosing. The NHP half-life observed for ORKA-001 supports the potential to achieve these extended dosing intervals given that other YTE-modified antibodies have had an approximately two to four times longer half-life in humans than in NHPs. In addition, the extended half-life of ORKA-001 could result in higher antibody exposures than risankizumab, which could lead to greater efficacy. &nbsp;</li>
<li>ORKA-001 binds to a similar epitope with similar affinity to risankizumab and shows equivalent potency across a variety of in vitro assays. ORKA-001 binds IL-23p19 with an affinity below five picomolar. Based on cryo-EM structural analysis, ORKA-001 binds to a nearly identical epitope to risankizumab. When assessed across four different assays in cell lines and primary cells, ORKA-001 also had comparable functional potency for IL-23 antagonism. These findings support that ORKA-001 has a validated mechanism of action and further derisk its development path.</li>
</ul>

ORKA

Oruka Therapeutics Announced New Preclinical Data On ORKA-001, A Novel Extended Half-life Monoclonal Antibody Targeting IL-23p19, At The European Academy Of Dermatology And Venereology Congress

Emergent BioSolutions Announced It Has Secured Approximately $400M In Orders In 2024 And 2025 Associated With Its Vaccinia, Smallpox And Mpox Product Portfolio

JMP Securities analyst Aaron Hecht maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Market Outperform and raises the price target from $170 to $210.

JMP Securities Maintains Market Outperform on Lennar, Raises Price Target to $210

ABBV

AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 mg Or 30 mg) In Patients With Moderate-to-severe Atopic Dermatitis

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=18266891&amp;u=https%3A%2F%2Fwww.iridium.com%2F&amp;a=Iridium+Communications+Inc.">Iridium Communications Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), a leading provider of global voice and data satellite communications, today announced that the 3rd Generation Partnership Project (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=3188554480&amp;u=https%3A%2F%2Fwww.3gpp.org%2F&amp;a=3GPP">3GPP</a>) accepted Iridium's request to extend the functionality of Narrowband Internet of Things (NB-IoT) for Non-Terrestrial Networks (NTN) into the Work Plan for 3GPP Release 19 as an official Work Item. This will pave the way for Iridium's satellite service to be accessible via industry standard chipsets, furthering the company's progress in developing and deploying its newest service, Iridium NTN Direct℠, over the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=2436757427&amp;u=https%3A%2F%2Fwww.iridium.com%2Fnetwork%2F&amp;a=Iridium%C2%AE+Network">Iridium&#xAE; Network</a>. Born from the company's Project Stardust initiative, the Iridium NTN Direct service being announced today is expected to be the world's first truly global&nbsp;5G NB-IoT service. <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=945366429&amp;u=https%3A%2F%2Fwww.3gpp.org%2Fspecifications-technologies%2Freleases%2Frelease-19&amp;a=3GPP+Release+19">3GPP Release 19</a>&nbsp;is currently scheduled to be completed in the fourth quarter of 2025.
&nbsp;
In January 2024, Iridium announced <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=3667490169&amp;u=https%3A%2F%2Finvestor.iridium.com%2F2024-01-10-Iridium-Unveils-Project-Stardust-Developing-the-Only-Truly-Global%2C-Standards-Based-IoT-and-Direct-to-Device-Service&amp;a=Project+Stardust">Project Stardust</a> to enable NB-IoT NTN standards-based communication through its operational LEO constellation – and has since made considerable progress at a rapid pace. Iridium NTN Direct technical development is well underway, with a successful demonstration having taken place earlier this year in a lab environment. Iridium has also joined <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262807-1&amp;h=36862901&amp;u=https%3A%2F%2Fwww.gsma.com%2F&amp;a=GSMA%2C">GSMA,</a> and is continuing to advance development with additional trials and demonstrations scheduled for early next year.
"We're already well into our technology development, and we're excited about our progress and to see so much enthusiasm from the 3GPP community," said Greg Pelton, CTO, Iridium. "As a cloud-based service powered by the flexibility of our software-defined satellites and building upon recognized industry standards, we've been able to jump off to a super-fast start. Our team is really motivated to make this happen."
Iridium NTN Direct will offer the opportunity for smartphone companies, OEMs, chipmakers, mobile network operators (MNO) and related IoT developers who utilize 3GPP standards-based technology to leverage Iridium's existing network and globally allocated and coordinated spectrum, providing a global, low-latency LEO user experience.
"When it comes to providing D2D, we don't have to be first, but we have to be the best. Iridium NTN Direct is an important initiative for us, and we've been able to pivot on an unprecedented scale and make significant progress toward providing the best service," said&nbsp;Matt Desch, CEO, Iridium. "We're grateful for the wide industry support of our vision to expand access to Iridium's global lifeline service by enabling it for anyone with a cellular device."
The Iridium satellite constellation's crosslinked, LEO architecture and global L-band spectrum provide a service advantage versus other LEO and geostationary satellite networks. Certified to provide safety of life services by international regulatory bodies, the Iridium network is known for its reliability and continues to be the only network that provides connectivity everywhere on Earth. Operating in LEO, the Iridium constellation does not suffer from the same line-of-sight limitations, significant power requirements or outages that can affect entire regions from a single satellite as faced by geostationary systems.

IRDM

Iridium's Satellite Service Gains Momentum for 2025 Global 5G NB-IoT Expansion

CLMB

Climb Channel Solutions, Wholly Owned Subsidiary Of Climb Global Solution Announced The Addition Of  A-LIGN, A Security Vendor Leading The Industry In Compliance, To Its Global Offerings

Greg Lucas has been promoted to the role of Vice President and Chief Accounting Officer, effective as of the same date.

Management

Thermon Group Names Jan L. Schott As Senior Vice President And CFO, Effective October 14, 2024

Macquarie analyst Paul Golding initiates coverage on Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Outperform rating and announces Price Target of $20.

Initiation

CLSK

Macquarie Initiates Coverage On Cleanspark with Outperform Rating, Announces Price Target of $20

Guidance

OCTO

Eightco Holdings Expects To Deliver Revenues Of $100M For 2025

Eightco Holdings Stated That It Has Made Significant Progress In 2024 By Improving Its Balance Sheet, Most Notably Through The Elimination Of $5.4M In Convertible Notes And Increasing Shareholder Equity By $23M

The scope of work includes constructing a new water treatment plant building, a storage facility, site improvements and demolition of the existing storage building and water treatment plant.
Southland was awarded this contract based on best value for this long-standing client. This award will be included in&nbsp;third quarter&nbsp;2024 backlog.

Contracts

SLND

Southland Holdings Secures $132M Contract To Construct New Water Treatment Plant For The Bureau Of Reclamation

KYMR

Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025

JMP Securities analyst Andrew Boone maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Market Outperform and raises the price target from $260 to $275.

DUOL

JMP Securities Maintains Market Outperform on Duolingo, Raises Price Target to $275

ALTR

Altair Announced Its Involvement In The £5.8M Performance Integrated Vehicle Optimization Technology Project, Supported By Innovate UK And The Advanced Propulsion Centre

Goldman Sachs analyst Brian Lee reiterates Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Buy and maintains $20 price target.

Reiteration

Goldman Sachs Reiterates Buy on Sunrun, Maintains $20 Price Target

STKH

Steakholder Foods Signed A Sales Agreement With Bondor Foods Ltd. to Supply Its Proprietary Plant-based Premixes For The Production Of A Line Of White Fish And Salmon Patties

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Reconnaissance Energy Africa Ltd Warrants (27/05/2024)

Reconnaissance Energy Africa Ltd Warrants (27/05/2024) (RECWF) Forecast

Reconnaissance Energy Africa Ltd Warrants (27/05/2024) (OTC:RECWF) Stock, Quote.Headers.trade-ideas